A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients

Clinical Cancer Research

Volumn 13, Issue 6, 2007, Pages 1875-1882

  Suzuki, Eiji ^a   Niwa, Rinpei ^b   Saji, Shigehira ^a   Muta, Mariko ^a   Hirose, Makiko ^a   Iida, Shigeru ^b   Shiotsu, Yukimasa ^b   Satoh, Mitsuo ^b   Shitara, Kenya ^b   Kondo, Masahide ^c   Toi, Masakazu ^a  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^b KYOWA HAKKO KOGYO CO LTD   (Japan)

^c UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; FC RECEPTOR; FCGR3A PROTEIN, HUMAN; FUCOSE; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER CELL CULTURE; CANCER PATIENT; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; EFFECTOR CELL; FUCOSYLATION; GENOTYPE; HUMAN; HUMAN CELL; NATURAL KILLER T CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TARGET CELL; ANIMAL; BREAST TUMOR; CHEMISTRY; CHO CELL; COMPARATIVE STUDY; CRICETULUS; DRUG EFFECT; EVALUATION; FEMALE; GENETICS; HAMSTER; IMMUNOLOGY; IMMUNOTHERAPY; LEUKOCYTE; MIDDLE AGED; PATHOLOGY; TUMOR CELL LINE;

ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BREAST NEOPLASMS; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; FEMALE; FUCOSE; HUMANS; IMMUNOTHERAPY; LEUKOCYTES; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, IGG;

EID: 34247854443     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1335     Document Type: Article

References (36)

1. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994; 1198:165-84.
2. Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992;89:4285-9.
3. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26.
4. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
5. Marty M, Cognetti F, Maraninchi D, et al. Randomised phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005;23:4265-74.
6. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
7. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:1659-72.
8. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23:3676-85.
9. Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000;18:3651-64.
10. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (Herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001;61: 4744-9.
11. 1 cell cycle arrest and tumour growth inhibition. J Biol Chem 2003;278: 23441-50.
12. Jackson JG, St Clair P, Sliwkowski MX, Brattain MG. Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects. Cancer Res 2004;64: 2601-9.
13. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Herceptin-induced inhibition of phosphatidylinositol-3k inase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumour action. Cancer Res 2002;62:4132-41.
14. Mohsin SK, Weiss HL, Gutierrez MC, et al. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol 2005;23:2460-8.
15. Lewis GD, Figari I, Fendly B, et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 1993;37:255-63.
16. Leget GA, Czuczman MS. Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol 1998; 10:548-51.
17. Gopal AK, Press OW. Clinical applications of anti-CD20 antibodies. J Lab Clin Med 1999;134:445-50.
18. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003;22:7359-68.
19. Koene HR, Kleijer M, Algra J, von Roos D, dem Born AE, de Haas M. FcgRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell FcgRIIIa, independently of the FcgRIIIa-48L/R/H phenotype. Blood 1997;90:1109-14.
20. Wu J, Edberg JC, Redecha PB, et al. A novel polymorphism of FcgRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 1997;100:1059-70.
21. Gennari R, Menard S, Fagnoni F, et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumours overexpressing HER2. Clin Cancer Res 2004;10: 5650-5.
22. Arnould L, Gelly M, Penault-Liorca F, et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 2006;94:259-67.
23. Shields RL, Lai J, Keck R, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcgRIII and antibody-dependent cellular toxicity. J Biol Chem 2002;277:26733-40.
24. Shinkawa T, Nakamura K, Yamane N, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003;278:3466-73.
25. Niwa R, Shoji-Hosaka E, Sakurada M, et al. Defucosylated anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T cell leukemia and lymphoma. Cancer Res 2004;64:2127-33.
26. Okazaki A, Shoji-Hosaka E, Nakamura K, et al. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgRIIIa. J Mol Biol 2004;336: 1239-49.
27. Niwa R, Hatanaka S, Shoji-Hosaka E, et al. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 is independent of FcgRIIIa functional polymorphism. Clin Cancer Res 2004;10: 6248-55.
28. Nakamura K, Tanaka Y, Fujino I, Hirayama N, Shitara K, Hanai N. Dissection and optimization of immune effector functions of humanized anti-ganglioside GM2 monoclonal antibody. Mol Immunol 2000;37: 1035-46.
29. Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, et al. Establishment of FUT8 knock-out CHO cells; an ideal host cell line for producing completely defucosylated antibodies with enhanced ADCC. Biotechnol Bioeng 2004;87:614-22.
30. Kanda Y, Yamane-Ohnuki N, Sakai N, et al. Comparison of cell lines for stable production of fucose-negative antibodies with enhanced ADCC. Biotechnol Bioeng 2006;94:680-8.
31. Leppers-van de Straat FGJ, van der Pol WL, Jansen MD, et al. A novel PCR-based method for direct Fcg receptor IIIa (CD16) allotyping. J Immunol Methods 2000;242:127-32.
32. Kobayashi T, Sugita N, van der Pol WL, et al. The Fcγ receptor genotype as a risk factor for generalized early-onset periodontitis in Japanese patients. J Periodontol 2000;71:1425-32.
33. Prang N, Preithner S, Brischwein K, et al. Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines. Br J Cancer 2005;92:342-9.
34. Moretta A, Bottino C, Vitale M, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001;19:197-223.
35. Moretta A, Bottino C, Mingari MC, Biassoni R, Moretta L. What is a natural killer cell? Nat Immunol 2002;3:6-8.
36. Niwa R, Sakurada M, Kobayashi Y, et al. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res 2005;11:2327-36.